Literature DB >> 16400512

The effect of circumferential tumor location in clinical outcomes of rectal cancer patients treated with total mesorectal excision.

Suk-Hawn Lee1, Enrique Hernandez de Anda, Charles O Finne, Robert D Madoff, Julio Garcia-Aguilar.   

Abstract

PURPOSE: A positive circumferential resection margin is associated with a high risk of local recurrence and distant metastasis after total mesorectal excision for rectal cancer. The mesorectum is thinner anteriorly than posteriorly, and the risk of a positive resection margin may be higher for anterior than for posterior tumors. We sought to determine the effect of the tumor's position in the circumference of the rectum on the treatment and outcomes of rectal cancer patients treated by total mesorectal excision.
METHODS: We retrospectively analyzed 401 patients with rectal cancer staged by preoperative endorectal ultrasound and treated by sharp mesorectal excision with or without neoadjuvant therapy. Tumors were classified into four groups (anterior, posterior, lateral, and circumferential) according to the location of deepest point of penetration on endorectal ultrasound. Differences in recurrence and survival rates were analyzed with logistic regression analysis.
RESULTS: Of the 401 tumors, 27 percent were anterior, 26 percent posterior, 32 percent lateral, and 15 percent circumferential. The groups did not differ in age, gender, tumor distance from the anal verge, or tumor grade. The ultrasound and pathology stages were more advanced in the circumferential group, and the proportion of uT4 tumors was higher in the anterior group. Circumferential and anterior tumors were more likely to receive preoperative adjuvant radiation. After an average follow-up of 44 months, 20 percent of patients had developed recurrence (13 percent distant, 6 percent local, and 1 percent distant and local). Recurrence was associated with advanced tumor stage, tumor proximity to the anal verge, and no preoperative adjuvant therapy. Early tumor stage and preoperative chemoradiation were associated with lower recurrence and improved survival. When tumor stage was controlled for, patients with poor or undifferentiated tumors and male patients with anterior tumors were shown to have a higher risk of recurrence or death. The estimated five-year disease-free survival for the entire group was 73 percent.
CONCLUSIONS: Tumor stage is the main criterion to estimate prognosis in rectal cancer patients. The position of the tumor within the circumference of the rectum may provide valuable clinical information. Anterior tumors tend to be more advanced and, at least in male patients, has a higher risk of recurrence and death than tumors in other locations.

Entities:  

Mesh:

Year:  2005        PMID: 16400512     DOI: 10.1007/s10350-005-0186-6

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  13 in total

Review 1.  The total mesorectal excision specimen for rectal cancer: a review of its pathological assessment.

Authors:  Jeremy R Parfitt; David K Driman
Journal:  J Clin Pathol       Date:  2006-10-17       Impact factor: 3.411

Review 2.  Patterns of local recurrence in rectal cancer after a multidisciplinary approach.

Authors:  Jose M Enríquez-Navascués; Nerea Borda; Aintzane Lizerazu; Carlos Placer; Jose L Elosegui; Juan P Ciria; Adelaida Lacasta; Luis Bujanda
Journal:  World J Gastroenterol       Date:  2011-04-07       Impact factor: 5.742

3.  Endoluminal stapler prototype for rectal transection.

Authors:  F J Pérez Lara; A Ferrer Berges; H Oliva Muñoz
Journal:  Tech Coloproctol       Date:  2017-04-25       Impact factor: 3.781

4.  A comparison of the localization of rectal carcinomas according to the general rules of the Japanese classification of colorectal carcinoma (JCCRC) and Western guidelines.

Authors:  Akira Tanaka; Sotaro Sadahiro; Toshiyuki Suzuki; Kazutake Okada; Gota Saito
Journal:  Surg Today       Date:  2017-03-07       Impact factor: 2.549

Review 5.  Extended abdominoperineal excision vs. standard abdominoperineal excision in rectal cancer--a systematic overview.

Authors:  Sigmar Stelzner; Carsta Koehler; Juliane Stelzer; Anja Sims; Helmut Witzigmann
Journal:  Int J Colorectal Dis       Date:  2011-05-21       Impact factor: 2.571

6.  Factors related to preoperative assessment of the circumferential resection margin and the extent of mesorectal invasion by magnetic resonance imaging in rectal cancer: a prospective comparison study.

Authors:  Young-Wan Kim; Seung-Whan Cha; Juyon Pyo; Nam-Kyu Kim; Byung-Soh Min; Myeong-Jin Kim; Hoguen Kim
Journal:  World J Surg       Date:  2009-09       Impact factor: 3.352

7.  Risk factors for adverse outcome in patients with rectal cancer treated with an abdominoperineal resection in the total mesorectal excision trial.

Authors:  Marcel den Dulk; Corrie A M Marijnen; Hein Putter; Harm J T Rutten; Geerard L Beets; Theo Wiggers; Iris D Nagtegaal; Cornelis J H van de Velde
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

8.  Comparison of tumor recurrence between laparoscopic total mesorectal excision with sphincter preservation and laparoscopic abdominoperineal resection for low rectal cancer.

Authors:  Jin-Tung Liang; Jason Chia-Hsien Cheng; Kuo-Chin Huang; Hong-Shiee Lai; Chia-Tung Sun
Journal:  Surg Endosc       Date:  2013-03-19       Impact factor: 4.584

9.  Transanal minimally invasive surgery for total mesorectal excision (TAMIS-TME): results and experience with the first 20 patients undergoing curative-intent rectal cancer surgery at a single institution.

Authors:  S Atallah; B Martin-Perez; M Albert; T deBeche-Adams; G Nassif; L Hunter; S Larach
Journal:  Tech Coloproctol       Date:  2013-11-23       Impact factor: 3.781

10.  Is transanal total mesorectal excision a reproducible and oncologically adequate technique? A pilot study in a single center.

Authors:  Matteo Rottoli; Lydia Hanna; Neil Kukreja; Alok Pancholi; Henk Wegstapel
Journal:  Int J Colorectal Dis       Date:  2015-10-21       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.